

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
17 February 2022 (17.02.2022)



(10) International Publication Number
WO 2022/034241 A1

(51) International Patent Classification:

A61K 31/137 (2006.01) *A61M 15/00* (2006.01)
A61K 31/56 (2006.01) *A61P 11/06* (2006.01)
A61K 9/00 (2006.01) *A61P 11/08* (2006.01)
A61K 9/72 (2006.01)

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(21) International Application Number:

PCT/EP2021/072718

(22) International Filing Date:

16 August 2021 (16.08.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2012742.9 14 August 2020 (14.08.2020) GB

(71) Applicant: **NORTON (WATERFORD) LIMITED**
[IE/IE]; Unit 301, IDA Industrial Park, Cork Road, Water-
ford (IE).

(72) Inventors: **O'NEILL, Brian Paul**; c/o Teva Pharmaceuti-
cals Ireland, Unit 301, IDA Industrial Park, Cork Road, Wa-
terford (IE). **SHAH, Hardik Kirtikumar**; c/o Teva Phar-
maceuticals Ireland, Unit 301, IDA Industrial Park, Cork
Road, Waterford (IE). **BLAIR, Julian Alexander**; c/o Te-
va Pharmaceuticals Ireland, Unit 301, IDA Industrial Park,
Cork Road, Waterford (IE). **EDLIN, Chris David**; c/o Te-
va Pharmaceuticals Ireland, Unit 301, IDA Industrial Park,
Cork Road, Waterford (IE). **MCKEON, Shane Michael**; c/
o Teva Pharmaceuticals Ireland, Unit 301, IDA Industrial
Park, Cork Road, Waterford (IE).

(74) Agent: **ELKINGTON AND FIFE LLP**; Prospect House,
8 Pembroke Road, Sevenoaks Kent TN13 1XR (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: AN INHALABLE FORMULATION OF FLUTICASONE PROPIONATE AND ALBUTEROL SULFATE

(57) Abstract: This invention relates to a fixed-dose dry powder inhalation formulation comprising fluticasone propionate and albuterol sulfate, together with an α -lactose monohydrate carrier. In the formulation, the albuterol sulfate stabilises fluticasone propionate.

WO 2022/034241 A1